Trials / Terminated
TerminatedNCT00695448
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2 dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1059615 | GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit. |
Timeline
- Start date
- 2008-06-24
- Primary completion
- 2009-03-31
- Completion
- 2009-03-31
- First posted
- 2008-06-11
- Last updated
- 2017-07-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00695448. Inclusion in this directory is not an endorsement.